For the twelve months ended Sep 30, 2026, Cardio Diagnostics Holdings Inc. reported $15.2K of revenue and -$6.49M of net income.
CDIO revenue was $3.6K in fiscal Q3 2026 (ended Sep 30, 2026), up 25.7% from a year earlier and down 33.0% from the prior quarter. For the full fiscal 2025 it was $14.8K, down 57.5% from fiscal 2024. It rose in 3 of the last 4 fiscal years.
CDIO net income was -$1.73M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.71M a year earlier. For the full fiscal 2025 it was -$6.50M, compared with -$8.38M in fiscal 2024.
CDIO diluted EPS was -$0.59 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$3.71.
CDIO free cash flow was -$1.52M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.56M a year earlier. For the full fiscal 2025 it was -$5.91M, compared with -$5.21M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.8K | $34.9K | $17.1K | $950 | $901 |
| Research and development | $641.2K | $228.0K | $145.2K | $40.4K | $31.5K |
| Selling, general and admin | $5.03M | $6.92M | $6.94M | $4.40M | $470.6K |
| Operating income | -$6.48M | -$8.37M | -$7.24M | -$4.55M | -$620.4K |
| Interest expense | $14.8K | $18.6K | $6.74M | - | - |
| Pre-tax income | -$6.50M | -$8.38M | -$8.38M | -$4.66M | -$620.4K |
| Income tax | - | - | - | $0 | $0 |
| Net income | -$6.50M | -$8.38M | -$8.38M | -$4.66M | -$620.4K |
| EPS, basic | -$3.71 | -$9.35 | -$19.80 | -$45.30 | -$15.90 |
| EPS, diluted | -$3.71 | -$9.35 | -$19.80 | -$45.30 | -$15.90 |
| Diluted shares | 1.8M | 896,424 | 422,837.767 | 102,922.767 | 38,774.067 |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $0 | $7.83M | $1.28M | $4.12M | $512.8K |
| Receivables | $8.1K | $18.6K | $5.0K | $0 | $901 |
| Current assets | $5.92M | $8.79M | $2.77M | $5.89M | $803.5K |
| Total assets | $7.77M | $10.62M | $4.46M | $6.25M | $1.10M |
| Current liabilities | $604.8K | $631.7K | $841.1K | $1.95M | $124.4K |
| Total liabilities | $793.1K | $1.06M | $1.50M | $1.95M | $33.9K |
| Shareholders' equity | $6.97M | $9.56M | $2.96M | $4.30M | $1.07M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.73M | -$4.99M | -$5.67M | -$5.09M | -$585.3K |
| Capital expenditures | $187.3K | $214.8K | $575.7K | - | - |
| Free cash flow | -$5.91M | -$5.21M | -$6.25M | - | - |
| Investing cash flow | -$419.3K | -$404.2K | -$794.3K | -$368.0K | -$364.0K |
| Financing cash flow | $3.43M | $11.94M | $3.63M | $9.06M | $1.23M |
| Stock-based compensation | $110.2K | $2.59M | $1.28M | $0 | $60.0K |
| Depreciation and amortization | $65.2K | $19.7K | $19.2K | $16.0K | $16.0K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue growth, YoY | -57.5% | 104.5% | 1696.3% | 5.4% | - |
| Operating margin | -43737.5% | -23977.9% | -42440.4% | -478784.3% | -68862.2% |
| Net margin | -43832.5% | -24028.2% | -49087.8% | -490630.0% | -68862.2% |
| Free cash flow margin | -39893.1% | -14926.5% | -36612.0% | - | - |
| Return on equity | -93.2% | -87.7% | -283.2% | -108.4% | -58.1% |
| Return on assets | -83.7% | -79.0% | -187.7% | -74.6% | -56.3% |
| Current ratio | 9.79 | 13.92 | 3.29 | 3.02 | 6.46 |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6K | $5.4K | $2.7K | $3.6K | $2.9K | $7.5K | $940 | $4.5K | $6.6K | $7.9K | $15.9K | $5.3K |
| Research and development | $174.3K | $162.9K | $129.8K | $154.8K | $189.0K | $178.5K | $118.8K | $204.6K | $5.2K | $7.3K | $10.8K | $7.5K |
| Selling, general and admin | $1.34M | $1.14M | $1.46M | $1.12M | $1.33M | $1.30M | $1.28M | $41.2K | $1.42M | $1.29M | $4.12M | $1.49M |
| Operating income | -$1.73M | -$1.50M | -$1.78M | -$1.46M | -$1.71M | -$1.68M | -$1.63M | -$1.52M | -$1.41M | -$1.28M | -$4.16M | -$1.54M |
| Interest expense | $2.3K | $3.4K | $3.4K | $2.3K | $3.1K | $4.7K | $4.7K | $3.1K | $3.9K | $5.8K | $5.8K | $96.1K |
| Pre-tax income | -$1.73M | -$1.50M | -$1.79M | -$1.47M | -$1.71M | -$1.68M | -$1.64M | -$1.52M | -$1.41M | -$1.29M | -$4.16M | -$1.39M |
| Net income | -$1.73M | -$1.50M | -$1.79M | -$1.47M | -$1.71M | -$1.68M | -$1.64M | -$1.52M | -$1.41M | -$1.29M | -$4.16M | -$1.39M |
| EPS, basic | -$0.59 | -$0.51 | -$0.63 | -$0.79 | -$0.98 | -$0.97 | -$0.97 | - | -$1.73 | -$1.71 | -$5.93 | - |
| EPS, diluted | -$0.59 | -$0.51 | -$0.63 | -$0.79 | -$0.98 | -$0.97 | -$0.97 | - | -$1.73 | -$1.71 | -$5.93 | - |
| Diluted shares | 3.0M | 3.0M | 2.8M | - | 1.8M | 1.7M | 1.7M | - | 814,762 | 753,587 | 702,574 | - |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $0 | $0 | $0 | $0 | $6.36M | $7.97M | $9.69M | $7.83M | $1.98M | $1.31M | $1.56M | $1.28M |
| Receivables | $3.5K | $3.9K | $4.3K | $8.1K | $11.2K | $12.9K | $9.6K | $18.6K | $14.1K | $7.5K | $19.0K | $5.0K |
| Current assets | $4.35M | $6.16M | $7.74M | $5.92M | $6.93M | $8.70M | $10.54M | $8.79M | $2.63M | $2.14M | $2.59M | $2.77M |
| Total assets | $6.08M | $7.93M | $9.56M | $7.77M | $8.79M | $10.40M | $12.28M | $10.62M | $4.48M | $4.00M | $4.33M | $4.46M |
| Current liabilities | $249.6K | $359.2K | $491.4K | $604.8K | $398.4K | $369.6K | $540.6K | $631.7K | $308.7K | $376.1K | $685.7K | $841.1K |
| Total liabilities | $366.0K | $499.8K | $656.0K | $793.1K | $637.3K | $671.8K | $905.0K | $1.06M | $795.3K | $922.5K | $1.29M | $1.50M |
| Shareholders' equity | $5.72M | $7.43M | $8.90M | $6.97M | $8.15M | $9.72M | $11.38M | $9.56M | $3.69M | $3.07M | $3.04M | $2.96M |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.52M | -$1.34M | -$1.56M | -$1.36M | -$1.39M | -$1.57M | -$1.40M | -$1.39M | -$1.16M | -$1.21M | -$1.23M | -$1.69M |
| Capital expenditures | $0 | $0 | $1.8K | $0 | $162.8K | $18.7K | $5.8K | $3.6K | $23.2K | $167.9K | $20.0K | $537.1K |
| Free cash flow | -$1.52M | -$1.34M | -$1.56M | -$1.36M | -$1.56M | -$1.59M | -$1.41M | -$1.40M | -$1.18M | -$1.38M | -$1.25M | -$2.22M |
| Investing cash flow | -$60.5K | -$46.8K | -$63.7K | -$78.4K | -$257.8K | -$35.7K | -$47.4K | -$54.6K | -$78.6K | -$201.1K | -$69.9K | -$566.9K |
| Financing cash flow | -$67.4K | -$101.2K | $3.59M | $195.6K | $40.0K | -$115.0K | $3.31M | $7.29M | $1.91M | $1.16M | $1.58M | -$93.5K |
| Stock-based compensation | $24.3K | $24.4K | $24.7K | $24.1K | $24.8K | $30.8K | $30.6K | $22.4K | $22.6K | $26.7K | $2.52M | $62.0K |
| Depreciation and amortization | $6.0K | $5.6K | $5.5K | $5.7K | $5.7K | $8.5K | $45.4K | $5.3K | $4.8K | $4.8K | $4.8K | $4.8K |
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 25.7% | -28.3% | 185.1% | -21.2% | -56.6% | -5.0% | -94.1% | -15.0% | -34.4% | 356.2% | - | 458.9% |
| Operating margin | -48193.8% | -27950.5% | -66598.4% | -41159.5% | -59950.9% | -22457.5% | -173463.8% | -33608.2% | -21412.9% | -16295.6% | -26105.3% | -29039.5% |
| Net margin | -48254.3% | -28012.5% | -66722.3% | -41219.9% | -60053.8% | -22517.7% | -173943.0% | -33672.6% | -21467.6% | -16365.9% | -26140.0% | -26156.9% |
| Free cash flow margin | -42225.6% | -25044.1% | -58357.2% | -38308.0% | -54509.7% | -21273.1% | -149562.6% | -30938.2% | -17942.3% | -17513.3% | -7866.9% | -41859.3% |
| Current ratio | 17.44 | 17.15 | 15.76 | 9.79 | 17.39 | 23.55 | 19.49 | 13.92 | 8.51 | 5.69 | 3.78 | 3.29 |
Source: XBRL data Cardio Diagnostics Holdings Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported May 15, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CDIO | $15.2K | -3.8% | -$6.49M | -42721.9% | $5.4M |
| IDXX | $4.66B | +11.9% | $1.18B | 25.4% | $55.67B |
| ORKA | - | - | -$132.89M | - | $6.92B |
| LNTH | $1.56B | +2.4% | $269.90M | 17.3% | $6.61B |
| NEOG | $883.99M | -0.3% | -$56.10M | -6.3% | $2.64B |
| CLDX | $158.0K | -93.9% | -$309.06M | -195608.9% | $2.45B |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.70B |
| QDEL | $2.59B | -4.5% | -$369.20M | -14.2% | $829.5M |
| ACHV | - | - | -$114.04M | - | $697.7M |